AcelRx Pharmaceuticals, a developer of innovative therapies for the treatment of acute pain, has appointed Gina Ford as Vice President of Commercial Strategy.
Ford has been working with AcelRx as a consultant since 2013 and has been instrumental in the development of a commercial strategy for Zalviso (sufentanil sublingual tablet system), a drug-device combination product now approved in Europe for the management of acute moderate-to-severe post-operative pain in adult patients. In her new role Ford will be responsible for developing the commercial plan for ARX-04 in the US, Europe and other regions.
Before joining the AcelRx management team, Ford was sole proprietor of One Joule, a commercial strategy consulting company. Before this she was President of Accesia, a wholly owned subsidiary of Patient Services, and held several leadership roles at Ipsen, a global pharmaceutical company focusing on neurology, endocrinology and urology-oncology.
